NCT03075826View on ClinicalTrials.gov

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Myeloproliferative Neoplasms
Interventions
DRUG

SGI-110

subcutaneously at a dose of 60 mg/m2

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER